POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP 149 MG
POTASSIUM CHLORIDE : 149 MG · DIN 02485699 · B. BRAUN MEDICAL INC
Health Canada status: MARKETED
What is POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP?
POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP 149 MG contains POTASSIUM CHLORIDE : 149 MG. It is listed in the Health Canada Drug Product Database under DIN 02485699, held by B. BRAUN MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 25-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP used for?
Treatment of potassium deficiency states when oral replacement is not feasible. Restricted to the preparation of admixtures for intravenous infusion.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02485699 |
|---|---|
| Brand name | POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP |
| Generic / active ingredient | POTASSIUM CHLORIDE : 149 MG |
| Manufacturer | B. BRAUN MEDICAL INC |
| Strength | 149 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA01 POTASSIUM CHLORIDE |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Mar-2020 |
| Original market date | 2020-03-25 00:00:00 |
How is it administered?
For IV infusion after dilution. Rate usually ≤10 mEq/h (max 40 mEq/h in emergencies). Max 24h dose 200-400 mEq. Must be thoroughly mixed. Pharmacy bulk package must be used within 4 hours of entry.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard USP storage usually applies, but field requires text-based extraction). Use within 4 hours of penetration.
How is it supplied?
250 mL Excel containers (Pharmacy Bulk Packages), packaged 24 per case. Container is PVC, DEHP, and latex free.
Contraindications
Hypersensitivity to ingredients; diseases with high potassium levels; hyperkalemia; renal failure; conditions with potassium retention or where potassium/chloride additives are detrimental.
Warnings and precautions
FATAL IF GIVEN BY DIRECT INFUSION. Must be diluted. Risk of fatal cardiac arrhythmia, hyperkalemia, and aluminum toxicity. Not for direct injection. Use with caution in cardiac disease.
Is POTASSIUM CHLORIDE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP
What can be used instead?
Other Canadian products sharing ATC code B05XA01 POTASSIUM CHLORIDE. 7 of 17 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE | 20 mEq / 10 ML | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 00402206 |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE | 200 mEq / 100 ML | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02480034 |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP | 149 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00037869 |
| POTASSIUM CHLORIDE INJECTION | 10 mEq / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241676 |
| POTASSIUM CHLORIDE INJECTION | 20 mEq / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241677 |
| POTASSIUM CHLORIDE INJECTION | 40 mEq / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02241679 |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE, USP (2 MEQ/ML) | 2 mEq | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02231673 |
| POTASSIUM CHLORIDE INJ 149MG/ML USP | 149 MG | LIQUID | AYERST LABORATORIES | CANCELLED POST MARKET | DIN 00645842 |
| POTASSIUM CHLORIDE INJ 149MG/ML USP | 149 MG | LIQUID | SABEX INC | CANCELLED POST MARKET | DIN 00398047 |
| POTASSIUM CHLORIDE INJ 2MEQ/ML | 2 mEq | LIQUID | INTERNATIONAL MEDICATION SYSTEMS LTD. | CANCELLED POST MARKET | DIN 00243884 |
Who else supplies POTASSIUM CHLORIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. POTASSIUM CHLORIDE appears in 158 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.